New findings from the SELECT trial indicate that semaglutide (Wegovy—Novo Nordisk) reduces the risk of major heart complications—heart attacks, strokes, and CV deaths—by 20%. The 5-year randomized trial of approximately 17,500 patients is the first to demonstrate that an obesity drug can have long-term CV benefits.

A new study in JAMA Network Open found that as drug overdose deaths have reached unprecedented levels in the United States, evidence-based treatments for substance use are severely underused.

According to the American Heart Association (AHA), significant disparities for stroke risk factors exist between Black adults and non-Black adults who have had a stroke.

In July, FDA approved nirsevimab-alip (Beyfortus—Sanofi/AstraZeneca). A few weeks later, on August 3, 2023, CDC’s ACIP voted unanimously to recommend the broad use of the new drug to infants and high-risk children for protection against respiratory syncytial virus (RSV).

FDA has issued new draft guidance geared toward industry regarding considerations for designing clinical trials involving psychedelic drugs.